Xenon Pharmaceuticals (XENE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
February 27, 2025 4:01 PM ESTPhase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch
First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year
Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year
Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025
Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor
Conference call at 4:30 pm ET today
VANCOUVER,... More
